Barbara Bishop
Neurology · Virginia Beach, VANPI 1588736946
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,089 of the $12,133 with a category attached, or 83.1%. It is spread thinly across 48 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $4,169 and has fallen 92.2% since, to $327 in 2025.
Across 518 payments — averaging $23.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$2K
- AbbVie$1K
- AstraZeneca$1K
- Sanofi$983
- UCB, Inc.$627
- Biogen$614
- plus $6K from 42 others
What the payments were for
- Consulting fees$1,0509%
- Travel & lodging$2382%
- Food & beverage$10,08983%
- Education$7566%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCREVUS$1,170
- ULTOMIRIS$737
- VNS - Sentiva$405
- NURTEC ODT$238
- XCOPRI$237
- NOURIANZ$133
- Leqembi$122
- UBRELVY$108
How this compares
$12,133 in reported general payments places this provider in the 75th percentile of 474 neurology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 42 | $375,405 |
| Nurtec OdtRimegepant Sulfate | 50 | $88,641 |
| AptiomEslicarbazepine Acetate | 44 | $70,358 |
| Emgality PenGalcanezumab-Gnlm | 74 | $68,901 |
| FingolimodFingolimod Hcl | 16 | $60,908 |
| Teriflunomide | 111 | $52,485 |
| BriviactBrivaracetam | 23 | $30,919 |
| Glatiramer Acetate | 15 | $26,001 |
| RytaryCarbidopa/Levodopa | 11 | $15,424 |
| Aimovig AutoinjectorErenumab-Aooe | 18 | $13,320 |
| Memantine Hcl | 303 | $13,168 |
| Emgality SyringeGalcanezumab-Gnlm | 12 | $12,832 |
| QuliptaAtogepant | 11 | $12,631 |
| Dalfampridine ErDalfampridine | 38 | $11,926 |
| Carbamazepine ErCarbamazepine | 56 | $6,069 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt, Dilantin | $128 | $93,04468 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $106 | $70,35844 claims |
| UCB, Inc.Briviact | $627 | $30,91923 claims |
| Amneal Pharmaceuticals LLCRytary | $140 | $15,42411 claims |
| AbbVieQulipta | $1,253 | $12,63111 claims |
| Upsher-smith Laboratories LLCTopiramate | $42 | $2,671149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 474 neurology providers in Virginia.
Other neurology in Virginia Beach
- Michelle BetzVirginia Beach$250K
- Amelito B MalapiraVirginia Beach$227K
- Patrick KilhennyVirginia Beach$102K
- Ramsey FalconerAlexandria$2M
- Robert ShinCharlottesville$1.7M
- Heidi CraytonVienna$1.5M
- Mark LandrioWinchester$631K
- Catherine HamRichmond$603K
- Jill CramerChristiansburg$598K
- Rahul DaveFairfax$540K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.